<ѻý>Anti-PD-1 Drugs Impress as Frontline Therapy for Early, Unfavorable Hodgkin'sѻý> 3-year PFS of 99%, OS of 100% with nivolumab-chemo, high response rate with pembrolizumab Dec 16, 2022
<ѻý>No Blaming Common Antihypertensives for Pancreatic Cancer, Study Suggestsѻý> Some reassurance on widely prescribed dihydropyridine calcium channel blockers Dec 15, 2022
<ѻý>New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCTѻý> Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk Dec 14, 2022
<ѻý>'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLLѻý> Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease Dec 14, 2022
<ѻý>C3 Pathway Inhibitor May Change Practice for Paroxysmal Nocturnal Hemoglobinuriaѻý> Iptacopan improved hemoglobin without transfusion versus current standard of care Dec 14, 2022
<ѻý>High-Dose Chemo, ASCT Improves Survival in Primary CNS Lymphomaѻý> European trial is "practice-changing as of today," says U.S. expert Dec 13, 2022
<ѻý>Prolonged Responses in DLBCL Spark Talk of a Cure With Bispecific Antibodyѻý> Most complete responses lasted 24 months or longer after limited-duration glofitamab Dec 13, 2022
<ѻý>Blinatumomab-Chemo Consolidation a 'New Standard' in MRD-Negative B-ALLѻý> Phase III study showed 58% reduction in the risk of death versus chemo alone Dec 13, 2022
<ѻý>Pediatric Hodgkin Lymphoma Survivors Experience Accelerated Epigenetic Agingѻý> Data from St. Jude cohort show higher rates of neurocognitive impairment Dec 13, 2022
<ѻý>Direct-Acting Antivirals Linked to Improved Outcomes in Chronic Hepatitis Cѻý> All-cause mortality rate significantly lower in treated versus untreated group Dec 13, 2022
<ѻý>Durable Platelet Response in Immune Thrombocytopenia With Efgartigimodѻý> Glycoprotein receptor inhibitor produces four times as many responses as placebo Dec 12, 2022
<ѻý>Black Patients Less Likely to Get Advanced Treatments for PEѻý> Also less likely for patients on Medicare and Medicaid Dec 12, 2022
<ѻý>AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCTѻý> Similar outcomes if patients went directly to transplant or received intensive salvage first Dec 11, 2022
<ѻý>Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myelomaѻý> Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients Dec 11, 2022
<ѻý>Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphomaѻý> Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone Dec 11, 2022
<ѻý>Rigid In-Hospital Diet Offers No Advantage in Patients After HSCTѻý> "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
<ѻý>Higher Brain Cancer Risk After CT Exam in Childhoodѻý> Study suggests one radiation-induced brain cancer expected per 10,000 persons receiving a head CT Dec 09, 2022
<ѻý>Less Is More Wins Again: Avoiding Node Dissection in Early Breast Cancerѻý> First comparison of targeted sentinel node assessment shows no difference in recurrence rates Dec 09, 2022
<ѻý>Adding AKT Inhibitor Doubles PFS in Advanced, HR-Positive Breast Cancerѻý> In phase III trial, capivasertib benefited patients with or without AKT pathway alterations Dec 09, 2022
<ѻý>Oral SERD Tops Fulvestrant for PFS in ER-Positive Breast Cancerѻý> Camizestrant also led to meaningful PFS improvements in those with detectable ESR1 mutations Dec 09, 2022
<ѻý>Pharmacogenomic Results Clear to Young Cancer Patients' Familiesѻý> But few guardians shared these results with other care providers Dec 09, 2022
<ѻý>Small Study Shows Most Crohn's Patients With Anal Cancer Survivedѻý> 15 of 24 were alive and cancer free at 5.5 years of follow-up Dec 09, 2022
<ѻý>Continuing CDK4/6 Inhibitor Beyond Progression No Help in Metastatic Breast Cancerѻý> Prior therapy, baseline mutations confound results; "intriguing" benefit with PD-L1 inhibitor Dec 09, 2022
<ѻý>Pausing Endocrine Therapy for Pregnancy Safe in Early Breast Cancerѻý> Study suggests no increased risk of cancer recurrence versus historical control Dec 09, 2022
<ѻý>T-DXd Continues Winning Streak in Metastatic, HER2-Positive Breast Cancerѻý> Trastuzumab deruxtecan improves survival in second- and later-line settings Dec 08, 2022
<ѻý>Neoadjuvant T-DXd Active in HER2-Low Breast Cancerѻý> Response rates on the order of 58-68%, with or without endocrine therapy Dec 08, 2022
<ѻý>Can Just Minutes of Daily Activity Prolong Life?ѻý> Benefits included all-cause, heart, and cancer-related mortality risk reduction Dec 08, 2022
<ѻý>Everolimus Fails Again as Adjuvant Therapy for High-Risk Breast Cancerѻý> No improvement in the overall analysis but a hint of benefit in premenopausal patients Dec 08, 2022
<ѻý>Assay Predicts Breast Cancer Patients Who Will Benefit From Ovarian Suppressionѻý> Low score suggests improved outcomes with ovarian suppression plus adjuvant endocrine therapy Dec 07, 2022
<ѻý>First-Line CDK4/6 Thumps Chemo in Aggressive, Advanced Breast Cancerѻý> Doubling of PFS could be death knell for combination chemotherapy in difficult-to-treat subgroup Dec 07, 2022
<ѻý>MRI-Targeted Biopsy for Prostate Cancer Reduces Risk of Overdiagnosisѻý> Though at the cost of delayed diagnosis of some clinically significant cancers Dec 07, 2022
<ѻý>Metastasis 'Doorway' May Lead to Racial Disparities in Breast Cancerѻý> Density of cellular complex after neoadjuvant therapy tied to cancer subtypes, may be targetable Dec 07, 2022
<ѻý>Cost Savings With Pharmacist-Driven Substitutions of Oncology Biosimilarsѻý> Regional clinical pharmacists helped community oncology practices navigate logistics, financials Dec 07, 2022
<ѻý>Xeljanz Cancer Risks Detailedѻý> New paper provides full results from ORAL Surveillance trial Dec 07, 2022
<ѻý>I'm a Neurologist, Hear Me Roarѻý> If I wasn't believed when seeking care, what chance do non-physicians have? Dec 06, 2022
<ѻý>Decoding Cancerѻý> A conversation with Harold Varmus, MD, who received the Nobel Prize in Physiology or Medicine in 1989 Dec 06, 2022 podcast
<ѻý>Can Oncologists Reduce the Suicide Risk in Their Prostate Cancer Patients?ѻý> Barriers exist in identifying risk, but strategies are available Dec 06, 2022
<ѻý>Aging U.S. Population a Challenge for Oncologistsѻý> Older patients will have different care goals, preferences, geriatric oncologist says Dec 05, 2022
<ѻý>Year in Review: Acute Lymphoblastic Leukemiaѻý> New ways to use CAR T-cell therapy and treatment de-intensification strategies Dec 05, 2022